Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making

Value in Health

Volumn 5, Issue 4, 2002, Pages 347-358

  Annemans, Lieven ^a,b,g   Moeremans, Karen ^a   Mutimer, David ^c   Schneeberger, Helmut ^d   Milligan, Don ^e   Kubin, Maria ^f  

^a Health Economics/Disease Management   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^f BAYER AG   (Germany)

^g NONE   (Belgium)

Author keywords

Analytical model; CMV; Cost effectiveness; Early assessment; Liver transplant; Preemption; Prophylaxis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR;

ARTICLE; BAYES THEOREM; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DECISION MAKING; DIAGNOSTIC TEST; DRUG COST; DRUG EFFICACY; DRUG SPECIFICITY; FRANCE; GERMANY; HEALTH CARE FINANCING; HEALTH ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; KIDNEY DISEASE; LIVER TRANSPLANTATION; NEUTROPENIA; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RELAPSE; RESOURCE ALLOCATION; STATISTICAL MODEL; THROMBOCYTOPENIA; UNITED KINGDOM;

EID: 0041488687     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.54117.x     Document Type: Article

References (23)

1. de Jong MD, Galasso GJ, Gazzard B, et al. Mini review. Summary of the II international symposium on cytomegalovirus. Antiviral Res 1998;39:141-62.
2. Hebart H, Kanz L, Jahn G, Einsele H. Management of cytomegalovirus infection after solidorgan or stem-cell transplantation. Current guidelines and future prospects. Drugs 1998;55:59-72.
3. Griffiths PD. Prophylaxis against CMV infection in transplant patients. J Antimicrob Chemother 1997;39:299-301.
4. McCarthy JM, Karim MA, Krueger H, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993;55:1277-82.
5. Falagas ME, Arbo M, Ruthazer R, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997;63:1595-601.
6. Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. Bone Marrow Transplant 1997;19:241-8.
7. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346:69-74.
8. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-8.
9. Noble S, Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998;56:115-46.
10. Mauskopf JA, Richter A, Annemans L, Maclaine G. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Pharmacoeconomics 2000;18:239-51.
11. Aitken C, Barrett-Muir W, Millar C, et al. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol 1999;37:2804-7.
12. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998;11:533-54.
13. Cohen DJ, Taira DA, Berezin R, et al. Costeffectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation 2001;104:3039-45.
14. Zwart-van Rijkom JE, van Hout BA. Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of platelet Iib/Iiia inhibitor for stenting trial. Eur Heart J 2001;22:1476-84.
15. Gane E, Saliba F, Valdecases GJC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-33.
16. Falagas ME, Snydman DR. Recurrent cytomegalovirus disease in solid-organ transplant recipients. Transplant Proc 1995;27:S34-7.
17. Stratta RJ, Shaefer MS, Cushing KA, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992;127:55-64.
18. Einarson TR, Arikian SR, Doyle JJ. Rank-order stability analysis (ROSA): testing pharmacoeconomic data. Med Decis Making 1995;15:367-72.
19. Whiting JF, Martin J, Zavala E, Hanto D. The influence of clinical variables on hospital costs after orthotopic liver transplantation. Surgery 1999;125:217-22.
20. Tsevat J, Snydman DR, Pauker SG, et al. Which renal transplant patients should receive cytomegalovirus immune globulin? A costeffectiveness analysis. Transplantation 1991;52:259-65.
21. Darrikhuma IM. Development of a renal transplant clinical pathway: one hospital's journey. AACN Clin Issues 1999;10:270-84.
22. Annemans L, Genesté B, Jolain B. Early modeling for assessing health and economic outcomes of drug therapy. Value Health 2000;3:427-34.
23. Annemans L, Giaccone G, Vergnenègre A. The cost-effectiveness of paclitaxel (Taxol®) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. Anticancer Drugs 1999;10:605-15.